|
MechanismNMDA receptor antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-targeted therapies
100 Clinical Results associated with New Medical Enzymes Ag
0 Patents (Medical) associated with New Medical Enzymes Ag
100 Deals associated with New Medical Enzymes Ag
100 Translational Medicine associated with New Medical Enzymes Ag